23andMe is dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company’s web-based service tells consumers what their DNA says about their health, traits and ancestry.
- Founded 2006
- Partnered 2017
- IPO 2021
Why we invested
An adverse FDA ruling nearly hobbled 23andMe. Rather than succumb, Anne and her team proved resilient, eventually becoming the only company with FDA clearance to provide genetic health testing reports directly to consumers. This tenacity and product advantage, combined with an unrivaled and growing dataset, positioned 23andMe to become an early stage therapeutics platform with vast potential.